poisar

Stocks · News reference

Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year

Benzinga Newsdesk

Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases,

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PALI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Benzinga Newsdesk

    Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated

    linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The findings connect

    PALI